Idiopathic Inflammatory Myopathies
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
150%
Cell Therapy
150%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
SandozRapcabtagene autoleucel
Prevail TherapeuticsBaricitinib
Kyverna TherapeuticsKYV-101
Clinical Trials (3)
Total enrollment: 162 patients across 3 trials
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Start: Dec 2024Est. completion: Jul 2030123 patients
Phase 2Recruiting
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
Start: Oct 2021Est. completion: Sep 202315 patients
Phase 2Completed
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
Start: Aug 2024Est. completion: Feb 202724 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 162 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.